TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11297610

Group type: EXPERIMENTAL
Intervention: 22-kDa recombinant human GH (rhGH) at a dosage of 0.15 IU/kg/day for 1 week
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 22-kDa recombinant human GH (rhGH)
Number of subjects: 17
Study: 9869946

Group type: EXPERIMENTAL
Intervention: Ultrarapid train stimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional programmed electrical stimulation (PES)
Number of subjects: 50
Study: 8311540

Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol (50 mg/200 micrograms twice daily)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Piroxicam (10 mg twice daily)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Naproxen (375 mg twice daily)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol
Number of subjects: 643

Group type: COMPARATOR
Intervention: Diclofenac/misoprostol, Piroxicam, Naproxen
Number of subjects: 643
Study: 2952162

Group type: EXPERIMENTAL
Intervention: Heliosit‐orthodontic (light cured adhesive)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Right‐on (chemically activated adhesive)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Heliosit‐orthodontic
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 122
Study: 30245114

Group type: EXPERIMENTAL
Intervention: Predictive scores for NOMI based on risk factors identified (renal insufficiency, use of cardiopulmonary bypass, intra-aortic balloon pump support, reexploration for bleeding, renal replacement therapy, packed red blood cells ≥ 4 units)
Number of subjects: 8748

Group type: COMPARATOR
Intervention: Control group (non-NOMI patients)
Number of subjects: 8748
Study: 28126612

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) curriculum for pediatric residents (n = 24)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 45
Study: 25265403

Group type: EXPERIMENTAL
Intervention: Theory-based video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stress management video (control)
Number of subjects: 0
Study: 22555773

Group type: EXPERIMENTAL
Intervention: 1.4 mg/m2 eribulin mesylate alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.7 mg/m2 eribulin mesylate plus 200 mg ketoconazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 10
Study: 22182758

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs)
Number of subjects: 102087

Group type: EXPERIMENTAL
Intervention: Blood Microscopy
Number of subjects: 102087

Group type: COMPARATOR
Intervention: Presumptive Diagnosis (Control)
Number of subjects: 102087
Study: 18053995

Group type: EXPERIMENTAL
Intervention: Pen device of follitropin-alpha (Gonal-f)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional syringe of follitropin-alpha (Gonal-f)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both pen device and conventional syringe of follitropin-alpha
Number of subjects: 100
Study: 16150858

Group type: EXPERIMENTAL
Intervention: Exisulind 400 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Exisulind 200 mg
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 12727766

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 147

Group type: COMPARATOR
Intervention: Non-supplementation
Number of subjects: 147

Group type: COMPARATOR
Intervention: Breastfed children
Number of subjects: 147
Study: 10898676

Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (200, 400, or 600 mg every 8 hours [TID] and 300 mg every 12 h [BID]) for 4 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Abacavir with zidovudine (200 mg TID or 300 mg BID) for 8 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Abacavir (300 mg BID) with zidovudine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Abacavir and zidovudine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 79
Study: 8836245

Group type: EXPERIMENTAL
Intervention: Warm-discrimination study with innocuous heat stimuli at 36 and 43 degrees C, applied as repetitive 5-s contacts to the volar forearm.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Discrimination between noxious and innocuous heat stimuli at 40 and 50 degrees C.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Discrimination between tonic innocuous cold and tonic cold pain with water immersion at 20.5 degrees C and 6.02 degrees C.
Number of subjects: 27
Study: 1356527

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (im)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Gonadotrophin releasing hormone (intranasally)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo (intranasally)
Number of subjects: 257
Study: 3917348

Group type: EXPERIMENTAL
Intervention: Serum digoxin concentrations (nil, low, high therapeutic values)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 12
Study: 29506572

Group type: EXPERIMENTAL
Intervention: Electrical moxibustion
Number of subjects: 138

Group type: COMPARATOR
Intervention: Traditional indirect moxibustion
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study: 26445821

Group type: EXPERIMENTAL
Intervention: Radiofrequency contact‐force catheter ablation (CFCA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Second‐generation cryoballoon ablation (CB‐AdvA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CFCA
Number of subjects: 56

Group type: COMPARATOR
Intervention: CB‐AdvA
Number of subjects: 56
Study: 24854612

Group type: EXPERIMENTAL
Intervention: Home monitoring with nurse visits on the 2nd, 3rd, and 5th days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 84
Study: 23009186

Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Ketamine with adjunctive atropine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Ketamine with adjunctive metoclopramide
Number of subjects: 338
Study: 19749086

Group type: EXPERIMENTAL
Intervention: Michigan's Exemplary Physical Education Curriculum (EPEC)
Number of subjects: 1464

Group type: COMPARATOR
Intervention: Standard PE curricula
Number of subjects: 1464
Study: 17591128

Group type: EXPERIMENTAL
Intervention: Closed-loop anaesthesia delivery system (CLADS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual control of propofol delivery
Number of subjects: 40
Study: 16102546

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 34
Study: 12132062

Group type: EXPERIMENTAL
Intervention: IV nefopam 0.15 mg/kg in 10 mL saline
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV tramadol 0.5 mg/kg in 10 mL saline
Number of subjects: 90

Group type: COMPARATOR
Intervention: IV saline (control)
Number of subjects: 90
Study: 11136320

Group type: EXPERIMENTAL
Intervention: Liver ultrasonography or CT
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Evaluation of symptoms
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: CEA measurement
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Other modalities
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Curative treatment for recurrence
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Diagnostic procedures for curative resected recurrence
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Ultrasonography and colonoscopy
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Routine follow-up by CEA measurement, chest radiography, and physical examination
Number of subjects: 496
Study: 9542781

Group type: EXPERIMENTAL
Intervention: CyA‐NF (Sandimmun Neoral)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CyA‐ST
Number of subjects: 15
Study: 7917935

Group type: EXPERIMENTAL
Intervention: Serum neuron-specific enolase (S-NSE)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Serum lactate dehydrogenase (S-LDH)
Number of subjects: 27
Study: 3277562

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 250 mg orally every 12 hours
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 500 mg orally every 12 hours
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cefaclor, 500 mg orally every eight hours
Number of subjects: 61
Study: 31931512

Group type: EXPERIMENTAL
Intervention: Deferred grazing (intermittent grazing)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Grazing exclusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (traditional continuous grazing)
Number of subjects: 6
Study: 29753297

Group type: EXPERIMENTAL
Intervention: Nurse practitioner care coordination
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 28139192

Group type: EXPERIMENTAL
Intervention: Tourniquet inflation during cementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: No tourniquet during cementation
Number of subjects: 40
Study: 25600123

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 day, placebo days 2 to 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazolin days 1 to 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin and clindamycin 1 day, placebo days 2 to 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin and clindamycin days 1 to 5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 23499607

Group type: EXPERIMENTAL
Intervention: School-located vaccination against influenza (SLV-I)
Number of subjects: 13561

Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 13561
Study: 21572151

Group type: EXPERIMENTAL
Intervention: ETN 25 mg twice a week with 6‐8 mg/week MTX (E+M group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: ETN alone (E group)
Number of subjects: 151
Study: 18288617

Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg t.i.d)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Sucralfate (1.0 t.i.d)
Number of subjects: 453
Study: 17027406

Group type: EXPERIMENTAL
Intervention: Chondroplasty
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Microfracture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Osteochondral Autograft Transplantation (OAT)
Number of subjects: 33
Study: 14583577

Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 15
Study: 10985711

Group type: EXPERIMENTAL
Intervention: Percutaneous or surgical revascularization
Number of subjects: 379

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Diabetes as a predictor of mortality
Number of subjects: 379
Study: 8628335

Group type: EXPERIMENTAL
Intervention: Fish-oil preparation (2.7 g of n-3 fatty acids daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo capsules (daily)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fish-oil preparation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 78
Study: 1591093

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tamoxifen plus prednisolone
Number of subjects: 46
Study: 29489721

Group type: EXPERIMENTAL
Intervention: 1.2 g·kg‐1 LMW (maltodextrin/dextrose/fructose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.2 g·kg‐1 HMW (Vitargo)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.066 g·kg‐1 PLA (noncaloric flavoring)
Number of subjects: 10
Study: 31361175

Group type: EXPERIMENTAL
Intervention: Physical exercise (balance, flexibility, strength training)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Music interventions (singing, listening to music, playing instruments)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 175
Study: 29954223

Group type: EXPERIMENTAL
Intervention: Nonexperimental (NE) designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized experiment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WSC designs with independent and dependent benchmark and NE arms
Number of subjects: 0
Study: 27072963

Group type: EXPERIMENTAL
Intervention: (125)I seed implantation
Number of subjects: 224

Group type: COMPARATOR
Intervention: Non-implantation (NIP)
Number of subjects: 224
Study: 24161233

Group type: EXPERIMENTAL
Intervention: Rapid screening (PCR testing for MRSA and VRE, chromogenic screening for HRE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional screening (chromogenic screening for MRSA and VRE)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chlorhexidine body-washing and hand hygiene improvement
Number of subjects: 13
Study: 22393898

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilastine 100 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg co-administered with ketoconazole 400 mg
Number of subjects: 30
Study: 21336170

Group type: EXPERIMENTAL
Intervention: Wide-open group (hinge at inner margin of lateral mass)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Narrow-open group (hinge at lamina margin)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Narrow-open group
Number of subjects: 102

Group type: COMPARATOR
Intervention: Wide-open group
Number of subjects: 102
Study: 16670121

Group type: EXPERIMENTAL
Intervention: Pediacel vaccine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae type b (DTwP-Hib) vaccine
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pediacel with meningococcal group C conjugate with diphtheria-derived protein CRM(197) (MCC-CRM)
Number of subjects: 241

Group type: COMPARATOR
Intervention: DTwP-Hib with meningococcal group C conjugate with diphtheria-derived protein CRM(197) (MCC-CRM)
Number of subjects: 241

Group type: COMPARATOR
Intervention: DTwP-Hib vaccine
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pediacel with meningococcal group C conjugate with tetanus toxoid (MCC-TT)
Number of subjects: 241

Group type: COMPARATOR
Intervention: DTwP-Hib with meningococcal group C conjugate with tetanus toxoid (MCC-TT)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pediacel and DTwP-Hib with MCC-CRM
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pediacel and DTwP-Hib
Number of subjects: 241
Study: 15640461

Group type: EXPERIMENTAL
Intervention: Rice bran oil diet (1/3 of total dietary fat)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Defatted rice bran diet (13-22 g dietary fiber/d)
Number of subjects: 40
Study: 12198012

Group type: EXPERIMENTAL
Intervention: Oral supplementation of 80 mg Cu (as copper sulfate). kg body wt(‐1). d(‐1) for 15 d
Number of subjects: 39

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 39
Study: 10192200

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a alone (4.5 MIU thrice weekly for 6 months)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a plus ribavirin (1000-1200 mg/day in combination with the same dose of interferon-alpha2a for 6 months)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Interferon-alpha2a plus ribavirin (1000-1200 mg/day)
Number of subjects: 53
Study: 7587687

Group type: EXPERIMENTAL
Intervention: fat‐glucose‐based group (intralipid)
Number of subjects: 17

Group type: COMPARATOR
Intervention: glucose‐based group (control)
Number of subjects: 17
Study: 2129094

Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsant therapy
Number of subjects: 0
Study: 6991560

Group type: EXPERIMENTAL
Intervention: Sealed teeth (molars)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sealed teeth (premolars)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Molar sealant failures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control teeth (unsealed)
Number of subjects: 0
Study: 31891212

Group type: EXPERIMENTAL
Intervention: 16% Alfalfa Hay (AH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20% Common Vetch Hay (CVH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0% Oat Hay (Control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 8%, 16%, 24% Alfalfa Hay (AH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10%, 20%, 30% Common Vetch Hay (CVH)
Number of subjects: 16
Study: 31740877

Group type: EXPERIMENTAL
Intervention: Post-intervention (group 2)
Number of subjects: 550
Study: 25282520

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg every 4 weeks for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25350595

Group type: EXPERIMENTAL
Intervention: Local melatonin (3 mg)
Number of subjects: 10
Study: 23226013

Group type: EXPERIMENTAL
Intervention: Azithromycin taken daily for one year
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Mannose-binding lectin deficiency
Number of subjects: 1037
Study: 19019050

Group type: EXPERIMENTAL
Intervention: Tramadol added to 0.25% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (0.25% bupivacaine alone)
Number of subjects: 30
Study: 17450417

Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI) focused on tobacco, alcohol, diet, weight, sun exposure, and work risk, delivered four times over 18 months, one every six months.
Number of subjects: 3031

Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI)
Number of subjects: 3031
Study: 15342891

Group type: EXPERIMENTAL
Intervention: Abbreviated asthma detection algorithm with 3 questions (question 1: asthma in the past 2 years, question 4: cough, chest tightness, trouble breathing, or wheezing with exercise, question 6: same symptoms in the morning or day in the past 4 weeks)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Complete asthma detection algorithm
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Asthma detection tool
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Reliability of the questionnaires
Number of subjects: 401
Study: 11271696

Group type: EXPERIMENTAL
Intervention: SNACs established in intervention schools
Number of subjects: 16
Study: 9777182

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 30
Study: 8150847

Group type: EXPERIMENTAL
Intervention: Topical therapeutic ultrasound followed by 10 minutes of passive stretching
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo ultrasound treatments and stretching
Number of subjects: 14
Study: 3170408

Group type: EXPERIMENTAL
Intervention: met‐hGH (2.67 mg/0.5 ml diluent, 3 days/wk)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (bacteriostatic water, 0.5 ml, 3 days/wk)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: met‐hGH
Number of subjects: 8
Study: 31154006

Group type: EXPERIMENTAL
Intervention: Teriflunomide sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leflunomide
Number of subjects: 0
Study: 28006886

Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg dexmedetomidine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg dexmedetomidine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sevoflurane at 0.7 MAC
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sevoflurane at 1.4 MAC
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sevoflurane at 2.0 MAC
Number of subjects: 144
Study: 25856121

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 24235903

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg taken 0 hours before bedtime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg taken 3 hours before bedtime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg taken 6 hours before bedtime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21336736

Group type: EXPERIMENTAL
Intervention: Gastrodin (40 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 200
Study: 19874989

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1421

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: ST-segment resolution at 4 h
Number of subjects: 1421
Study: 16963221

Group type: EXPERIMENTAL
Intervention: Victims of interpersonal trauma
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-victims of interpersonal trauma
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Trauma status (victims vs non-victims)
Number of subjects: 81
Study: 15831694

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 7800
Study: 12578152

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg after an overnight fast
Number of subjects: 18

Group type: COMPARATOR
Intervention: Telithromycin 800 mg after a standard high-fat breakfast
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg (both fasting and non-fasting)
Number of subjects: 18
Study: 10099075

Group type: EXPERIMENTAL
Intervention: bisoprolol/6.25 mg HCTZ (n = 155)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: amlodipine (n = 154)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: enalapril (n = 155)
Number of subjects: 541

Group type: COMPARATOR
Intervention: placebo (n = 79)
Number of subjects: 541
Study: 7857500

Group type: EXPERIMENTAL
Intervention: Hypericum extract LI 160 (300 mg three times daily for 4 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 2477463

Group type: EXPERIMENTAL
Intervention: Water‐Suppressed Proton Nuclear Magnetic Resonance Spectroscopy (1 HNMR) of plasma lipoproteins
Number of subjects: 75
Study: 1067690

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with penicillins or cephalosporins
Number of subjects: 132

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 132